CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 13.4% in December

CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 4,800,000 shares, a decline of 13.4% from the December 15th total of 5,540,000 shares. Based on an average daily trading volume, of 1,230,000 shares, the short-interest ratio is currently 3.9 days.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a research report on Tuesday, January 7th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $5.77.

Institutional Investors Weigh In On CytomX Therapeutics

Institutional investors have recently bought and sold shares of the business. Traphagen Investment Advisors LLC bought a new position in shares of CytomX Therapeutics during the 4th quarter worth about $31,000. Virtu Financial LLC acquired a new position in CytomX Therapeutics in the third quarter worth about $104,000. Geode Capital Management LLC lifted its stake in CytomX Therapeutics by 4.4% during the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after purchasing an additional 34,032 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in CytomX Therapeutics by 1.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock valued at $1,798,000 after purchasing an additional 16,359 shares in the last quarter. Finally, FMR LLC grew its stake in shares of CytomX Therapeutics by 17.3% in the 3rd quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock valued at $335,000 after purchasing an additional 41,949 shares during the period. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Trading Down 0.8 %

CTMX stock traded down $0.01 during trading on Friday, reaching $0.84. 620,234 shares of the stock were exchanged, compared to its average volume of 992,394. CytomX Therapeutics has a twelve month low of $0.79 and a twelve month high of $5.85. The company has a market capitalization of $65.74 million, a P/E ratio of 4.94 and a beta of 1.03. The stock has a 50 day simple moving average of $1.04 and a 200-day simple moving average of $1.15.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.23. The company had revenue of $33.43 million for the quarter, compared to analyst estimates of $18.92 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same quarter last year, the firm earned $0.04 EPS. Equities analysts predict that CytomX Therapeutics will post -0.05 EPS for the current year.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.